The ALS Association’s Post

In the crowded field of companies racing to discover the next blockbuster drug using artificial intelligence, Hong Kong and New York-based Insilico Medicine says it’s ahead of the pack. “We have achieved 17 preclinical candidates, which no other company has done before,” claims Alex Zhavoronkov, founder and co-CEO of Insilico, which is backed by blue-chip investors like Warburg Pincus and Qiming Venture Partners. (Disclosure: Zhavoronkov is a contributor to Forbes.) “In our entire pipeline, we had only one case in which we failed and then we actually restarted the program and succeeded in developing a preclinical candidate,” adds Zhavoronkov, who holds a Ph.D. in physics and mathematics from Moscow State University. “So we basically have a very high probability of success.”

In the crowded field of companies racing to discover the next blockbuster drug using artificial intelligence, Hong Kong and New York-based Insilico Medicine says it’s ahead of the pack. “We have achieved 17 preclinical candidates, which no other company has done before,” claims Alex Zhavoronkov, founder and co-CEO of Insilico, which is backed by blue-chip investors like Warburg Pincus and Qiming Venture Partners. (Disclosure: Zhavoronkov is a contributor to Forbes.) “In our entire pipeline, we had only one case in which we failed and then we actually restarted the program and succeeded in developing a preclinical candidate,” adds Zhavoronkov, who holds a Ph.D. in physics and mathematics from Moscow State University. “So we basically have a very high probability of success.”

In the crowded field of companies racing to discover the next blockbuster drug using artificial intelligence, Hong Kong and New York-based Insilico Medicine says it’s ahead of the pack. “We have achieved 17 preclinical candidates, which no other company has done before,” claims Alex Zhavoronkov, founder and co-CEO of Insilico, which is backed by blue-chip investors like Warburg Pincus and Qiming Venture Partners. (Disclosure: Zhavoronkov is a contributor to Forbes.) “In our entire pipeline, we had only one case in which we failed and then we actually restarted the program and succeeded in developing a preclinical candidate,” adds Zhavoronkov, who holds a Ph.D. in physics and mathematics from Moscow State University. “So we basically have a very high probability of success.”